Feb 10, 2020

Rubix LS, Who Previously Isolated Protein Binding Receptors in Ebola and Leishmaniasis, By Leveraging Rapid Real-Time Spectral Analysis of Key Proteins, Has Adapted It’s Technology to Target The Coronavirus

Posted by

Rubix LS had previously engineered and deployed rapid diagnostic and elemental detection tools while actively working on studies of Ebola and Leishmaniasis, in both India and West Africa, which successfully resulted in the ability to real-time identify and target affected patient populations, as well as providing predictive patient diagnosis to aid in therapeutic intervention.

According to Rubix LS CEO Reginald Swift, “Our technology is currently being adapted specifically for 2019-nCoV by targeting amino acid isolates and mutative protein binding changes from bronchoalveolar fluid obtained through the breath of individuals. The model transformation will be completed within the the coming days. Just as the first case of the coronavirus was reported in Massachusetts."

The World Health Organization (WHO) declared coronavirus (2019-nCoV) a global health emergency. The rapid scale in which China, U.S, U.K and now India have produced exposure symptoms to coronavirus, has according to reports, caused more than 362 deaths, with 17205 cases in China, and 11 US cases reported, including 1 in Massachusetts where Rubix LS is headquartered.

The CDC Newsroom telebriefing of January 30, 2020, stated the incubation period for coronavirus could be up to 14 days. When asked if it is possible to detect this virus before somebody is symptomatic, Dr. Nancy Messonnier from CDC responded, "We don't know yet, and we're looking closely to see if we can". In response Swift states "this is exactly where our innovative approach and technology becomes invaluable".

It was also confirmed, in a separate release by the CDC, that the virus has spread between two people in the United States, representing first instance of person-to-person exposure in the country.  According to the CDC, MERS, SARS, and now the two coronaviruses that have emerged, have caused serious illness and death in individuals that have been exposed.

Rubix LS uses Artificial Intelligence/Machine Learning (AI/ML) within it’s platform to specifically isolate protein binding receptor modifying behaviors that are able to target the prediction and precursor of the disease evolution and potential patient diagnosis.

“Our team has been working around the clock to refine the models for addressing these new epidemiological targets and to build high-level accuracy in the findings.” states Swift. “In addition to Artificial Intelligence, our platform utilizes several skin-based sensor technologies, that are configured with communication tools, and can detect and provide a rapid spectral analysis of key proteins in real-time". The resulting databank of biological profiles can then be cross referenced and indexed by major health agencies, and research institutions worldwide, to further fight the problem.

Rubix LS has optimized it’s AI/ML platform to rapidly characterizing the "spike protein" changes that identify key differences from what is observed through 2019-nCOV, SARS & MERS, within minutes of running it’s model. Leveraging the power and datastore of their platform, Rubix LS will compliment and augment epidemiological datasets gathered by other companies and organizations, to accurately target key configurations of mutation properties that represent a critical understanding in developing a vaccine.


 "Rubix LS is presently in contact with the CDC to immediately initiate the development of a program to begin a pilot study. It will also aggregate all compiled and collected data, to disseminate to the greater scientific community and WHO authorities, with the goal of helping to deploy robust countermeasure activities worldwide," concludes Swift.


For any questions regarding Rubix LS, please contact the Rubix LS team by info@rubixls.com

 or contact Reginald Swift directly at 855-639-5863, rswift@rubixls.com

For any questions regarding updates to 2019-nCOV please visit the cdc.gov website. 


About Rubix LS

Rubix LS has developed integrative and transformative virtual tools and technologies through deep disease research and development toward targeting detection and prevention mobilization to aid and facilitate government, industry and community actions toward eradication of deadly diseases and cancers. www.rubixls.com


Media Contact                                                                                          For Rubix LS Direct Contact

Daisy Gallagher, Chief Public Information Officer                           Reginald Swift, CEO Rubix LS

Direct: 202.465.0009                                                                             Direct: 855-639-5863 ext 700

newsroom@gallagherworldwide.com                                                 rswift@rubixls.com

See all Member News